Abstract: The embodiment of the present disclosure provides an imaging method for a dispersion energy spectrum of surface waves, an electronic device, and a storage medium. The imaging method includes: obtaining first surface wave data, and the first surface wave data corresponding to a space-time domain representation; processing the first surface wave data to obtain the second surface wave data, and the second surface wave data corresponding to a space-frequency domain representation; and processing the second surface wave data based on a preset algorithm to obtain a first imaging result, the first imaging result corresponding to a slowness-frequency domain representation.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The invention discloses a method for treating a disorder or a disease induced by an oxidative stress injury, including administering VEGF-B to a subject; and, a chemical containing VEGF-B protein, VEGF-B expressing plasmids, VEGF-B expressing viruses and/or VEGF-B expressing cells as active ingredients for treating a disorder or a disease induced by an oxidative stress injury. VEGF-B is a strong antioxidant having an intense anti-oxidative effect and capable of up-regulating antioxidant genes and down-regulating oxidant genes, and thus rescuing cellular and vascular degeneration under a pathologic condition. VEGF-B is the first member from the VEGF family to be recognized as a regulatory factor of anti-oxidation pathway, and therefore it can be used as a new medicament for anti-aging and anti-tumor purposes, and for treating varieties of degenerative and oxidative stress injury-related diseases.

Abstract: The invention discloses a method for treating a disease involving neoangiogenesis, including administering VEGF-B to a subject; and, a pharmaceutical composition containing VEGF-B protein, VEGF-B expressing plasmids, VEGF-B expressing viruses and/or VEGF-B expressing cells as active ingredients for treating a disease involving neoangiogenesis. The VEGF-B of the invention is able to bind to FGF2 receptors FGFR1 and FGFR2, induces the formation of FGFR1/VEGFR1 or FGFR2/VEGFR1 complex, inhibits the functions of FGFR1 and FGFR2, up-regulates Spry4 expression, and inhibits FGF2 from activating Erk, thus inhibiting neoangiogenesis.

Abstract: A method for treating a degenerative disease or neurodegenerative disease in a mammalian subject is provided. The method provides administering VEGF-B polypeptide or functional variant or mimetic thereof in an amount effective to reduce or eliminate the degenerative disease in the mammalian subject without having any substantial angiogenic effect across all dosage levels.

Abstract: Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of stimulation. The present invention discloses that tPA is a specific PDGF-C activating protease, and that the CUB-domains in PDGF-CC directly interact with the protease, are required for efficient proteolysis, and released CUB-domains are tPA inhibitors. Preferably, the method and compositions of the present invention are used for simultaneously stimulating, or simultaneously inhibiting, thrombolysis and angiogenesis.

Abstract: VEGF-B is shown to be needed for cardiac muscle revascularization after heart infarction, and methods of promoting or stimulating vascular development, e.g. angiogenesis and/or arteriogenesis, particularly in ischemic mammals, are disclosed.

Abstract: Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of stimulation. The present invention discloses that tPA is a specific PDGF-C activating protease, and that the CUB-domains in PDGF-CC directly interact with the protease, are required for efficient proteolysis, and released CUB-domains are tPA inhibitors. Preferably, the method and compositions of the present invention are used for simultaneously stimulating, or simultaneously inhibiting, thrombolysis and angiogenesis.

Abstract: A method for modulating vasculogenesis or arteriogenesis or angiogenesis, especially for treating heart and limb ischemia, using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.

Abstract: PDGF-D, a new member of the PDGF/VEGF family of polypeptide growth factors, is described, as well as nucleotide sequences encoding, methods for producing, pharmaceutical compositions containing this new growth factor, and its antibodies and other antagonists. Also disclosed are transfected and transformed host cells expressing PDGF-D, and uses thereof in medical and diagnostic applications.

Abstract: PDGF-D, a new member of the PDGF/VEGF family of polypeptide growth factors, is described, as well as nucleotide sequences encoding, methods for producing, pharmaceutical compositions containing this new growth factor, and its antibodies and other antagonists. Also disclosed are transfected and transformed host cells expressing PDGF-D, and uses thereof in medical and diagnostic applications.

Abstract: Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of stimulation. The present invention discloses that tPA is a specific PDGF-C activating protease, and that the CUB-domains in PDGF-CC directly interact with the protease, are required for efficient proteolysis, and released CUB-domains are tPA inhibitors. Preferably, the method and compositions of the present invention are used for simultaneously stimulating, or simultaneously inhibiting, thrombolysis and angiogenesis.

Abstract: Non-human transgenic animals overexpressing PDGF-C and cells thereof have been created. The transgenic animals contain a nucleotide sequence that encodes for platelet derived growth factor C (PDGF-C) or an analog thereof, or a functional fragment of PDGF-C or analog thereof. These animals are useful for studying disease states characterized by overexpression of PDGF-C, as well as useful for evaluating therapies intended to treat such diseases.

Abstract: A method and kit for detecting the presence of tumor cells in an animal by detecting expression of VEGF-B186, determining an increased expression of VEGF-B186, or by determining an increased expression of VEGF-B186 relative to expression of VEGF-B167. The kit comprises a receptacle adapted to receive a sample and a means for detecting expression of VEGF-B186 from the sample. Also, a method for screening for anti-tumor agents.

Abstract: Method for inhibiting tumor cell formation or tumor cell growth, the method comprising administering to a patient in need thereof an antagonist to VEGF-B. Preferably, the antagonist is an anti-VEGF-B antibody, an antisense molecule, an RNAi molecule, a molecule for forming a triplex nucleic acid molecule with a VEGF-B encoding polynucleotide. Also disclosed are pharmaceutical compositions comprising the same.

Abstract: The present invention provides materials and methods for VEGF-B and PDGF therapy, especially therapy directed at stem cell recruitment, proliferation, and/or differentiation.

Abstract: A method for modulating vasculogenesis or arteriogenesis or angiogenesis, especially for treating heart and limb ischemia, using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.

Abstract: A method and kit for detecting the presence of tumor cells in an animal by detecting expression of VEGF-B186, determining an increased expression of VEGF-B186, or by determining an increased expression of VEGF-B186 relative to expression of VEGF-B167. The kit comprises a receptacle adapted to receive a sample and a means for detecting expression of VEGF-B186 from the sample. Also, a method for screening for anti-tumor agents.

Abstract: A method for modulating vasculogenesis or angiogenesis using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.

Abstract: VEGF-B is shown to be needed for cardiac muscle revascularization after heart infarction, and methods of promoting or stimulating vascular development, e.g. angiogenesis and/or arteriogenesis, particularly in ischemic mammals, are disclosed.